Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
MED13L encodes mediator complex subunit 13-like, a critical component of the CDK8 kinase module that regulates RNA polymerase II-mediated transcription. Heterozygous MED13L variants cause a syndromic intellectual disability characterized by global developmental delay, hypotonia, distinctive facial features, and variable congenital anomalies including cardiac defects. The phenotype overlaps with MED12-related syndromes, supporting a unified mediatoropathy spectrum. Inheritance is autosomal dominant, with most affected individuals harboring de novo variants. Clinical recognition of MED13L syndrome facilitates targeted genetic testing and management.
Genetic evidence comprises four unrelated de novo MED13L cases. A cohort of seven subjects with syndromic intellectual disability revealed two frameshift and one nonsense variant, including c.5545G>T (p.Glu1849Ter), in three patients, all confirmed as de novo (PMID:25712080). An additional de novo LoF MED13L variant was identified in one of three patients evaluated by targeted neurodevelopmental gene sequencing (PMID:27500536). These findings establish an autosomal dominant pattern without familial segregation.
The variant spectrum is dominated by loss-of-function alleles. Reported changes include single-nucleotide deletions and duplications causing frameshifts and premature termination. A representative truncating allele, c.5545G>T (p.Glu1849Ter), abolishes the C-terminal regulatory region and segregates with the core MED13L phenotype (PMID:25712080). Hypomorphic missense variants appear less frequently in classic MED13L syndrome but contribute to phenotypic variability in broader MED13L-related disorders.
Mechanistic studies support haploinsufficiency as the primary pathogenic mechanism. Splice-site variants at the exon 7 donor (c.1009+1G>C) lead to retention of intronic sequence, frameshift, and premature termination, consistent with loss of function (PMID:39181712). Analysis of five disease-associated missense mutations demonstrated reduced MED13L stability, aberrant subcellular localization, and impaired interaction with the CDK8 module, correlating with clinical severity (PMID:40500968).
In vitro and in vivo neuronal assays confirm relevance to cortical development. The truncating variant p.Gln1922Ter yields barely detectable MED13L protein and impairs dendritic branching in layer II/III pyramidal neurons, while RNAi-mediated knockdown of Med13L disrupts dendritic growth that is rescued by wild-type but not mutant constructs (PMID:36798993). These concordant functional data strengthen the causal link between MED13L haploinsufficiency and syndromic intellectual disability.
Taken together, genetic and experimental evidence supports a strong gene-disease association between MED13L and autosomal dominant syndromic intellectual disability. De novo loss-of-function variants in MED13L consistently produce a recognizable clinical syndrome, underpinned by mechanistic studies of haploinsufficiency. Key Take-home: MED13L loss-of-function variants cause a diagnosable autosomal dominant intellectual disability syndrome with established clinical and experimental validity.
Gene–Disease AssociationStrongFour unrelated de novo probands (three LoF [PMID:25712080], one nonsense [PMID:27500536]) and functional concordance across multiple models Genetic EvidenceModerateFour de novo MED13L variants in unrelated individuals establish an autosomal dominant pattern without familial segregation Functional EvidenceModerateFunctional assays demonstrate loss-of-function: intron retention, reduced protein stability, impaired neuronal morphology ([PMID:39181712],[PMID:36798993],[PMID:40500968]) |